SCHEMBL26108434

SCHEMBL26108434

Cn1c(C2=CCC3(CC2)CCN(C=CC=O)CC3)c(-c2ncc(OC3CC3)cn2)c2c(N)ncnc21

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ KCNH2 Q12809 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26107952 0.93 — —
SCHEMBL26106100 0.92 — —
SCHEMBL26108342 0.92 — —
SCHEMBL26108735 0.91 RET (0.31) —
SCHEMBL26109846 0.90 KCNH2 (0.36) KCNH2
SCHEMBL26107398 0.89 — —
SCHEMBL26105475 0.88 LRRK2 (0.32) —
SCHEMBL26104690 0.87 — —
SCHEMBL26108491 0.87 — —
SCHEMBL26108721 0.87 KCNH2 (0.33) KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO claimed
WO-2023192502-A1 SPIROBICYCLIC COMPOUNDS ACERAND THERAPEUTICS (USA) LIMITED (US) 2023-10-05 — — WO disclosed
Send feedback